Could a drug that targets the brain's hunger pathway help people with Bardet-Biedl syndrome?

NCT ID NCT07674290

Recruiting now Disease control Sponsor: Tom Hühne Source: ClinicalTrials.gov ↗

First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time

Summary

This study looks at how well setmelanotide works in real-world settings for people with Bardet-Biedl syndrome, a rare genetic condition that causes severe obesity and constant hunger. Researchers will track changes in body mass index, cholesterol, liver fat, and quality of life in both children and adults. The goal is to see if the drug can help control weight and improve overall health over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: setmelanotide
What this could lead to: If successful, this could confirm setmelanotide as a safe and effective long-term treatment for severe obesity and related health problems in Bardet-Biedl syndrome.
What could go wrong: This is a single-center observational study, not a blinded trial, so results may be less definitive. Setmelanotide requires lifelong use and may have side effects; not all patients may respond.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALSTROM SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alstrom syndrome Bardet-Biedl syndrome Hyperphagia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALSTROM SYNDROME BARDET BIEDL SYNDROME BARDET-BIEDL SYNDROME (BBS)

Contacts and locations

Locations

University Hospital Essen, Deparment of Pediatrics II
RECRUITING

Essen, 45147, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.